Merriman Wealth Management adds MiMedx Group Inc (MDXG) to its portfolio

MiMedx Group Inc (MDXG) : Merriman Wealth Management added new position in MiMedx Group Inc during the most recent quarter end. The investment management firm now holds 622,674 shares of MiMedx Group Inc which is valued at $5,137,061 , the company said in a statement filed on Jul 8, 2016 with the SEC.MiMedx Group Inc makes up approximately 1.43% of Merriman Wealth Management’s portfolio.

Other Hedge Funds, Including , Patten Patten Inctn boosted its stake in MDXG in the latest quarter, The investment management firm added 3,870 additional shares and now holds a total of 29,570 shares of MiMedx Group Inc which is valued at $243,953. MiMedx Group Inc makes up approx 0.03% of Patten Patten Inctn’s portfolio.Bnp Paribas Arbitrage Sa boosted its stake in MDXG in the latest quarter, The investment management firm added 16,906 additional shares and now holds a total of 31,233 shares of MiMedx Group Inc which is valued at $257,672. Integrated Investment Consultants sold out all of its stake in MDXG during the most recent quarter. The investment firm sold 6,000 shares of MDXG which is valued $48,360.

MiMedx Group Inc closed down -0.27 points or -3.29% at $7.93 with 13,97,183 shares getting traded on Wednesday. Post opening the session at $8.15, the shares hit an intraday low of $7.89 and an intraday high of $8.26 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

On the company’s financial health, MiMedx Group Inc reported $0.07 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Feb 23, 2016. Analyst had a consensus of $0.06. The company had revenue of $51.80 million for the quarter, compared to analysts expectations of $51.53 million. The company’s revenue was up 30.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.03 EPS.

Many Wall Street Analysts have commented on MiMedx Group Inc. Shares were Downgraded by First Analysis Sec on Apr 27, 2016 to ” Equal-Weight” and Lowered the Price Target to $ 9 from a previous price target of $14 .Shares were Reiterated by Needham on Apr 12, 2016 to “Strong Buy” and Lowered the Price Target to $ 12 from a previous price target of $13 .Shares were Reiterated by Needham on Apr 11, 2016 to “Strong Buy” and Lowered the Price Target to $ 12 from a previous price target of $13 .

MiMedx Group Inc. (MiMedx) is an integrated developer manufacturer and marketer of regenerative biomaterial products and bioimplants processed from human amniotic membrane. The Company’s biomaterial platform technologies include AmnioFix and EpiFix its tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through its donor program mothers delivering full-term Cesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. MiMedx processes the human amniotic membrane utilizing its Purion Process to produce an implant which is referred as an allograft. MiMedx is the supplier of amniotic tissue having supplied over 350000 allografts for application in the Wound Care Surgical Sports Medicine Ophthalmic and Dental sectors of healthcare. Its CollaFix technology combines a means of creating fibers from soluble collagen and a cross-linking process.

Leave a Reply

MiMedx Group Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on MiMedx Group Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.